Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2)

The role of Interleukin-32 in autoimmunity




Julkaisun tekijät: Albuquerque Rafael, Komsi Elina, Starskaia Inna, Ullah Ubaid, Lahesmaa Riitta

Kustantaja: WILEY

Julkaisuvuosi: 2021

Journal: Scandinavian Journal of Immunology

Tietokannassa oleva lehden nimi: SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Lehden akronyymi: SCAND J IMMUNOL

Volyymi: 93

Julkaisunumero: 2

Sivujen määrä: 9

ISSN: 0300-9475

eISSN: 1365-3083

DOI: http://dx.doi.org/10.1111/sji.13012

Verkko-osoite: https://onlinelibrary.wiley.com/doi/10.1111/sji.13012

Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/51228400


Tiivistelmä
Interleukin-32 (IL-32) is a pro-inflammatory cytokine that induces other cytokines involved in inflammation, including tumour necrosis factor (TNF)-alpha, IL-6 and IL-1 beta. Recent evidence suggests that IL-32 has a crucial role in host defence against pathogens, as well as in the pathogenesis of chronic inflammation. Abnormal IL-32 expression has been linked to several autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel diseases, and a recent study suggested the importance of IL-32 in the pathogenesis of type 1 diabetes. However, despite accumulating evidence, many molecular characteristics of this cytokine, including the secretory route and the receptor for IL-32, remain largely unknown. In addition, the IL-32 gene is found in higher mammals but not in rodents. In this review, we outline the current knowledge of IL-32 biological functions, properties, and its role in autoimmune diseases. We particularly highlight the role of IL-32 in rheumatoid arthritis and type 1 diabetes.

Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Last updated on 2022-07-04 at 18:16